Auteurs : Aurore Surun, Marie‐Églantine Dujaric, Isabelle Aerts, Daniel Orbach, Irène Jiménez, Hélène Pacquement, Gudrun Schleiermacher, Franck Bourdeaut, Jean Michon, Jean‐Claude K. Dupont, François Doz
Article publié dans : Pediatric Blood & Cancer, Volume65, Issue5, May 2018, e26916
Date de parution : 2018
DOI : https://doi.org/10.1002/pbc.26916
The European Paediatric Regulation was introduced in 2007 to facilitate access to new medicines for children. Our study explored accessibility of early‐phase trials in pediatric oncology, in line with the European Paediatric Regulation, to identify the reasons for not inviting patients to participate, parents’ refusal, or inclusion failure.
We conducted a retrospective chart review at Institut Curie, Paris, for all pediatric patients whose cancer progressed despite known effective treatments between July 2010 and December 2013.
Out of 100 patients in the palliative phase, 52 received one or more invitations to participate in early‐phase trials. Twenty parents declined the invitation, mainly prioritizing quality of life or fearing constraints. Fourteen inclusions failed despite parental approval, mostly due to rapid clinical deterioration. Five patients received no invitations because no early‐phase trials were available. Major reasons for noninclusion in the 43 remaining patients were presence of exclusion criteria or other physical factors, preference for conventional treatment, constraints, psychological factors, and follow‐up in another hospital after moving.
The Paediatric Regulation has led to increased availability of early‐phase trials. Better timing of the proposal, designing less constraining early‐phase trials, reducing waiting lists, and improving information for parents and children would facilitate pediatric access to new medicines.